Carfentanil
Viewing r1 — May 8, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Carfentanil is a synthetic opioid of the anilidopiperidine class. It is approximately 100 times more potent than fentanyl,[1][2] occupying the extreme end of the opioid potency spectrum. It activates opioid receptors in the brain, suppressing pain signaling and depressing the drive to breathe.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
No dose data on record for this route. The timings below are not a dose guide.
morphine, fentanyl, heroin +3 moremorphine, fentanyl, heroin, oxycodone, hydromorphone, methadone show less
Synthesized in 1974, carfentanil was developed for veterinary immobilization of large wildlife and marketed as Wildnil.[3] In 2002, Russian security forces aerosolized it during a Moscow theater hostage siege, killing approximately 130 people. Since 2016, it has appeared as an invisible adulterant in the illicit opioid supply, causing mass overdose deaths;[2] no approved human use exists in any jurisdiction.
Subjective effects include intense euphoria, pain suppression, heavy sedation, and a dissolving of anxiety. These effects are inferred entirely from opioid pharmacology — no controlled human data exist, and the onset-to-loss of consciousness window may be measured in seconds. Characteristic unsought effects include chest wall rigidity that mechanically blocks breathing, a slowing heartbeat, and rapid loss of consciousness.
Dependence liability is high, and the estimated lethal dose of roughly 20 µg[3] leaves no margin between an active and a fatal dose. Standard naloxone often fails — carfentanil binds opioid receptors in ways that resist displacement,[4] its effects outlast naloxone by hours,[5] and blood concentrations in survivors and fatalities overlap.[6][7] No controlled human studies have been published; the evidence base rests on veterinary pharmacology, forensic toxicology, and laboratory receptor data.
History[edit]
Discovery
Carfentanil was synthesized on May 2, 1974, at Janssen Pharmaceutica by a team led by Paul Janssen.[3] It emerged from the same structural series that had produced fentanyl in 1960,[8] with a U.S. patent granted in 1979.[3]
Veterinary use and the Moscow theater crisis
In 1986, carfentanil entered veterinary practice as Wildnil for remote dart immobilization of elephants, rhinoceroses, and other large wildlife;[3] commercial production ceased in 2003 due to diversion risk.[9] In October 2002, Russian security forces aerosolized carfentanil and remifentanil into Moscow's Dubrovka Theater during a hostage siege; approximately 130 of 850 hostages died, primarily from respiratory failure compounded by insufficient naloxone and improper positioning of unconscious victims.[10][11]
Illicit supply and international scheduling
Carfentanil entered the North American illicit drug supply in 2016 as an adulterant in heroin and counterfeit opioid tablets, with overdose deaths documented across ten US states;[2] standard laboratory screening missed it in 104 of 134 carfentanil-positive postmortem cases in Miami-Dade County alone.[12] China regulated it in March 2017,[3] and in December 2017 the WHO recommended the most stringent level of international control.[13]
The name carfentanil is a contraction of its systematic designation as 4-carbomethoxyfentanyl. In veterinary and law enforcement contexts, the Wildnil brand name persisted as a reference point long after production ceased. A single kilogram seizure at Vancouver airport in June 2016 represented millions of potential lethal doses[3]}; for drug policy analysts and first responders, the compound became shorthand for the escalating potency of the synthetic opioid supply.
Chemistry[edit]
Structural class
Carfentanil belongs to the 4-anilidopiperidine chemical class, sharing its core scaffold with fentanyl, sufentanil, alfentanil, and remifentanil.[14] What distinguishes it from fentanyl is a methyl ester group added at one position of the piperidine ring, which dramatically increases its opioid receptor affinity.[14] Its molecular formula is C₂₄H₃₀N₂O₃ (molecular weight 394.5 g/mol).
Physical properties
Carfentanil has no stereocenters — it is an achiral molecule with no active or inactive isomers.[14] The compound is highly lipophilic, meaning it crosses biological membranes rapidly and can be absorbed through intact skin, mucous membranes, and the lungs.[3] This was confirmed operationally when it was aerosolized as an incapacitating agent in 2002.[10]
Pharmacology[edit]
Mechanism of action
Carfentanil is a full opioid agonist — it activates the same receptors as morphine and fentanyl, but at far lower concentrations.[15] Receptor activation suppresses pain, produces sedation and euphoria, and depresses the drive to breathe in a dose-dependent way.
It locks opioid receptors into conformations that are 10–100 times harder for naloxone to displace than those produced by other opioids,[4] and it unbinds from those receptors far more slowly than other fentanyl analogs.[5] These two features make reversal markedly more difficult than for any other opioid in the illicit supply.
Pharmacokinetics
No controlled human pharmacokinetic studies exist. The estimated serum half-life is approximately 5.7 hours — longer than fentanyl's 3.7 hours[15] — and one metabolite retains potency comparable to the parent compound,[15][16] meaning effects can outlast what the half-life alone predicts. Naloxone's half-life is roughly 33 minutes, creating a high risk of renarcotization after apparent reversal.[17]
Neuroscience[edit]
Where it acts
Carfentanil activates opioid receptors concentrated in the brain's reward circuitry, pain-modulation centers, and the brainstem nuclei that control breathing.[18] In the mesolimbic pathway, this produces intense euphoria. In the brainstem, it slows the breathing rate and reduces the brain's sensitivity to rising carbon dioxide.[17]
Why it matters
As a radiolabeled PET tracer, [¹¹C]carfentanil is the most widely used tool for imaging opioid receptors in the living human brain.[19] Hundreds of studies using this tracer have mapped opioid receptor activity during pain, stress, social rejection, and addiction — at doses far below any pharmacological threshold.
Key unresolved questions include whether carfentanil's β-arrestin signaling[20] contributes to the speed and severity of respiratory arrest, and how much overdose lethality comes from the active metabolite versus the parent compound.[16] Evidence also suggests cardiovascular collapse in carfentanil overdose may involve brain signaling pathways distinct from classical opioid respiratory depression[21] — a distinction with implications for optimal rescue pharmacology.
Subjective Effects[edit]
Carfentanil has no characterizable subjective experience. The compound moves from first effect to loss of consciousness in seconds — a window so narrow that every documented human exposure is an unintentional overdose. What opioid pharmacology predicts as euphoria and sedation arrives already indistinguishable from overdose.
Compared to fentanyl — itself at the extreme end of clinically encountered opioid potency — carfentanil is approximately 50–100 times more potent for respiratory depression[5] and binds opioid receptors in a way far more resistant to naloxone reversal.[4] No other opioid in the illicit supply approaches this combination.
Effect Grid
No common dose exists for carfentanil in any context of human use. The compound was developed exclusively for veterinary immobilization of large wildlife (elephants, rhinoceroses) and has no approved human therapeutic indication. Essentially all documented human exposures are unintentional overdoses from adulterated heroin or counterfeit pills.
The concept of a common dose implies a range where most users experience characteristic effects with manageable risk. For carfentanil, no such range can be identified: the estimated lethal dose (~20 µg) is indistinguishable from any potentially experiential dose.
Forensic case series show substantial overlap between blood concentrations in surviving impaired individuals and fatal cases, confirming the absence of any predictable dose-response relationship.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual haze / noise · Visual processing suppression
Pain suppression · Physical fatigue · Bodily heaviness · Body high · Constipation · Muscle relaxation · Nausea · Spontaneous body sensations · Tactile euphoria · Abnormal heartbeat · Dizziness · Dry mouth · Excessive sweating · Sexual arousal suppression · Temperature dysregulation · Tingling / electric sensations · Vomiting · Muscle tension · Involuntary body movements · Nystagmus (eye wobbles) · Bodily dissociation
Body high · Constipation · Muscle relaxation · Nausea · Spontaneous body sensations · Tactile euphoria · Dizziness · Dry mouth · Excessive sweating · Sexual arousal suppression · Temperature dysregulation · Tingling / electric sensations · Vomiting · Muscle tension · Involuntary body movements · Nystagmus (eye wobbles) · Bodily dissociation
Focus suppression · Information processing suppression · Thought deceleration · Cognitive euphoria · Creativity suppression · Memory suppression · Motivation suppression · Confusion · Language suppression · Memory fragmentation · Thought disorganization · Amnesia
Cognitive euphoria · Creativity suppression · Memory suppression · Motivation suppression · Confusion · Language suppression · Memory fragmentation · Thought disorganization
Anxiety
Depersonalization · Derealization · Cognitive disconnection
Timeline
Slightly delayed onset compared to IV due to mucosal absorption. Effects emerge within 1–5 minutes. Rapid progression to loss of consciousness and respiratory depression expected at any pharmacologically active dose.
Maximal opioid effects if survived. Complete sedation, respiratory depression, bradycardia, and miosis. Duration estimated from fentanyl intranasal class data with extension for carfentanil's slower receptor dissociation.
Gradual decline complicated by active metabolite M2/M0 and slow µOR dissociation. Renarcotization risk persists as naloxone wears off far sooner than carfentanil's pharmacological effects resolve.
Residual sedation and cognitive impairment. Active metabolite continues to contribute opioid effects.
⚠ Do not drive or operate machinery for at least 24 hours after any carfentanil exposure; extended medical monitoring is required due to renarcotization risk.
Safety[edit]
- Acute toxicity
- Critical
- Chronic toxicity
- Critical
- Withdrawal
- Severe
- Tolerance buildup
- rapid
- Tolerance reset
- 14 days
- Physical
- High
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- High
- Cross-tol.
- morphine · fentanyl · heroin
Toxicity
Estimated lethal dose
The estimated human lethal dose is approximately 20 µg — equivalent to a few grains of table salt.[3] safety citation needed There is no meaningful therapeutic index for human use. The margin between any pharmacologically active dose and a lethal dose is effectively zero.
Postmortem and forensic data
Blood concentrations in carfentanil-only deaths range from <0.2 to 0.73 ng/mL,[6] while surviving impaired individuals show concentrations of <0.04–2.1 ng/mL[7] — ranges that overlap. No blood concentration reliably distinguishes survival from death. In polydrug deaths, concentrations reach up to 9.2 ng/mL.[22]
Heart and circulation
A slowed heart rate occurs consistently alongside respiratory depression in animal models,[23] including at PET tracer doses.[24] Cardiac arrest is a common cause of death in overdose.[5]
Chest wall rigidity
High doses can lock the chest wall and diaphragm muscles, mechanically preventing breathing independent of the brain's respiratory depression.[25] This compounds the central respiratory effect and accelerates fatal outcomes.
Detection challenges
Carfentanil is not detectable by standard drug screening — immunoassay panels and standard GC-MS miss it entirely; 104 of 134 carfentanil-positive cases in Miami-Dade County were initially missed by conventional screening.[12] Fentanyl test strips do not reliably detect it.[26] LC-MS/MS is required for reliable detection.[22][6]
Exposure routes
Toxicity occurs via injection, insufflation, ingestion, transdermal absorption through intact skin, mucous membrane absorption, and inhalation.[3] Occupational exposure is documented for veterinarians, law enforcement, first responders, and forensic laboratory workers.[3]
Psychological Risks
No controlled data on carfentanil-specific psychological effects exist. By class inference, acute risks include rapid progression from cognitive euphoria to confusion and loss of consciousness, delirium during partial recovery or incomplete reversal, amnesia for the exposure period, and acute anxiety and dysphoria if naloxone precipitates withdrawal. inferred
The compound's potency means the window between onset of subjective effects and unconsciousness is likely seconds to minutes for most routes. inferred
Tolerance & Dependence
No human studies on tolerance or dependence exist; all assessments are class-level inferences from opioid pharmacology. Tolerance develops via receptor desensitization, and carfentanil's signaling pattern[20] is associated with faster development than typical opioids.
Physical dependence follows the standard opioid withdrawal pattern — Anxiety, Dysphoria, muscle pain, sweating, runny nose, insomnia, and gastrointestinal distress. Severity has not been characterized but would be expected to be severe given the compound's extreme potency and long half-life. Dependence liability is high by class inference, and cross-tolerance is expected with all opioid agonists. inferred
Drug Interactions
The dominant risk is CNS depressant synergy: combining carfentanil with benzodiazepines, alcohol, other opioids, or gabapentinoids produces synergistic respiratory depression. Most carfentanil overdose deaths involve polydrug toxicity,[22] and because carfentanil enters the supply as an adulterant, co-exposure with other depressants is the norm.
Standard naloxone shows 10–100-fold reduced potency against carfentanil.[4] Nalmefene has superior reversal characteristics due to higher receptor affinity and a longer half-life,[27][28] and naltrexone is approximately 65 times more potent than naloxone at displacing carfentanil from opioid receptors.[4] CYP3A4/3A5 inhibitors — azole antifungals, macrolide antibiotics, HIV protease inhibitors, and grapefruit juice — are expected to increase carfentanil concentrations and toxicity.[29] safety citation needed
Contraindications
No substance-specific contraindication studies exist. The following are class-level inferences.
Absolute contraindications:
- Concurrent CNS depressant use — synergistic respiratory depression is the leading cause of carfentanil-associated death[22]
- Respiratory compromise — COPD, sleep apnea, and similar conditions lower the lethal threshold
- Absence of reversal agents — any exposure context without immediately available naloxone or nalmefene
Relative contraindications:
- CYP3A4/3A5 inhibitor co-administration — expected increase in blood concentrations[29]
- Liver impairment — reduced clearance may prolong and intensify effects
- Heart conditions — slowed heart rate is a documented effect[23] and may worsen pre-existing cardiac conduction problems
- Pregnancy — opioids cross the placenta; carfentanil's extreme potency amplifies fetal risk inferred
safety citation needed All contraindications are class-level inferences.
Harm Reduction[edit]
Forms & Identification
Carfentanil is never sold as a standalone product. It enters the drug supply as an invisible adulterant in heroin, counterfeit prescription pills, and powder sold as fentanyl. The compound is active at quantities far below visual detection — distinguishing a contaminated sample by appearance is impossible.
Standard fentanyl test strips do not reliably detect carfentanil,[26] and standard immunoassay drug panels miss it entirely.[12] Only LC-MS/MS provides definitive identification. A negative fentanyl strip result does not rule out carfentanil contamination.
Guidelines
- Never use alone. Carfentanil can cause unconsciousness and respiratory arrest within seconds. A witness who can call for help and administer naloxone is critical.
- Carry naloxone — and carry extra. Standard naloxone doses may be insufficient for carfentanil. Multiple doses should be immediately accessible.
- Start with a test dose. When using any unregulated opioid, use a small amount first and wait. This does not eliminate risk from carfentanil contamination — the compound is active at invisible quantities — but may reduce the probability of a full lethal exposure.
- Avoid mixing with other depressants. Benzodiazepines, alcohol, and other opioids dramatically increase the risk of fatal respiratory depression.
- Use supervised consumption sites where available. Trained staff with naloxone and emergency equipment provide the highest level of protection against overdose death.
Set & Setting
Carfentanil exposure is almost exclusively unintentional. There is no safe set or setting for deliberate use — the margin between an active and lethal dose is effectively zero. For people who use unregulated opioids, the single most important environmental factor is never using alone. A second person who can recognize overdose and administer naloxone is the only practical safeguard against a rapid fatal outcome.
Aftercare & integration. Carfentanil exposure is rarely deliberate, and aftercare is primarily medical. Anyone who survives a carfentanil-related overdose should remain under medical observation for several hours — the compound's long half-life and active metabolite create a sustained risk of renarcotization after initial naloxone reversal.
Physical recovery after opioid overdose may involve persistent fatigue, nausea, muscle soreness, and cognitive fog for 24–72 hours. Precipitated withdrawal from naloxone administration can produce intense anxiety, agitation, and pain. These symptoms are temporary but distressing, and medical support should be sought if they persist.
Overdose is a traumatic event for survivors and witnesses. Peer support organizations, crisis counseling, and harm reduction services can help with emotional recovery and safety planning to reduce future risk.
Recovery & Support
Opioid dependence — whether involving carfentanil, fentanyl, or heroin — is a treatable condition. Evidence-based options include:
- Opioid agonist therapy (methadone, buprenorphine) — reduces cravings, prevents withdrawal, and lowers overdose risk. This is the most effective treatment for opioid use disorder and can be maintained long-term.
- Naltrexone (extended-release injection) — blocks opioid effects and reduces relapse risk. Requires full detoxification before initiation.
- Peer support — organizations such as SMART Recovery and Narcotics Anonymous provide community-based support.
- Harm reduction services — syringe service programs, naloxone distribution, and supervised consumption sites reduce immediate risks while supporting pathways to treatment.
Recovery is not linear. Relapse is common and does not represent failure — it represents an ongoing condition requiring adjusted support.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency
- Slow, shallow, or stopped breathing
- Blue or gray lips and fingertips
- Gurgling or snoring sounds from an unconscious person
- Unresponsive to stimulation (sternal rub, loud voice)
- Chest wall rigidity — the chest feels stiff and does not rise with breaths
Immediate steps
- 1. Call emergency services immediately. Do not wait to see if the person recovers.
- 2. Administer naloxone (intranasal or intramuscular). Give a second dose after 2–3 minutes if there is no response. Carfentanil may require multiple naloxone doses — standard dosing is often insufficient.[4]
- 3. Place the person in the recovery position (on their side) to prevent aspiration.
- 4. Perform rescue breathing if the person is not breathing and training permits.
- 5. Stay with the person. Renarcotization is likely — carfentanil's effects outlast naloxone by hours.[17]
What to tell the dispatcher
State that the person is unresponsive with slowed or stopped breathing. Say "possible opioid overdose — may involve carfentanil or fentanyl structural analog." Provide the time symptoms were noticed and any substances known to have been used. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Reversal agents
Naloxone is the standard opioid antagonist but may require repeated or higher-than-standard doses for carfentanil. Nalmefene, where available, has superior reversal characteristics due to higher receptor affinity and a longer half-life.[27][28] Even after apparent reversal, prolonged medical monitoring is essential — carfentanil's half-life of approximately 5.7 hours far exceeds naloxone's 33-minute half-life.
Legal Status[edit]
Carfentanil is subject to the most stringent international drug controls, with no approved human use anywhere in the world.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| International | Schedule I and Schedule IV, 1961 Single Convention | Most stringent international control; WHO recommendation December 2017[13] |
| United States | Schedule II (Controlled Substances Act) | DEA ACSCN 9743; annual manufacturing quota 19 grams (2016); retains Schedule II due to historical veterinary use[9] |
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Possession: up to 7 years imprisonment and/or unlimited fine; supply: up to life imprisonment and/or unlimited fine[9] |
| Australia | Schedule 8 (Poisons Standard) | Added June 2017; controlled/restricted substance[9] |
| Canada | Controlled substance | Controlled under federal legislation[9] |
| European Union | Individually scheduled by member states | Formal risk assessment conducted by European drugs agency; widespread scheduling across member states |
| China | Controlled | Regulated March 2017 following identification as major illicit supply source[3] |
Legal status varies by jurisdiction and changes over time. This information is not legal advice.
references
- [1] ^Swanson DM, Hair LS, Strauch Rivers SR, et al. (2017) Fatalities Involving Carfentanil and Furanyl Fentanyl: Two Case Reports — Journal of analytical toxicology doi:10.1093/jat/bkx037
- [2] ^abcO'Donnell JK, Halpin J, Mattson CL, Goldberger BA, Gladden RM (2017) Deaths Involving Fentanyl, Fentanyl Analogs, and U-47700 - 10 States, July-December 2016. — MMWR. Morbidity and mortality weekly report doi:10.15585/mmwr.mm6643e1
- [3]
- [4]
- [5] ^abcdMann J, Samieegohar M, Chaturbedi A, et al. (2022) Development of a Translational Model to Assess the Impact of Opioid Overdose and Naloxone Dosing on Respiratory Depression and Cardiac Arrest — Clinical pharmacology and therapeutics doi:10.1002/cpt.2696
- [6] ^abcKahl JH, Gonyea J, Humphrey SM, Hime GW, Boland DM (2018) Quantitative Analysis of Fentanyl and Six Fentanyl Analogs in Postmortem Specimens by UHPLC-MS-MS — Journal of analytical toxicology doi:10.1093/jat/bky054